Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer

Koga, Chinami; Akiyoshi, Sayuri; Ishida, M.; Nakamura, Yoshiaki; Ohno, Shinji; Tokunaga, Eriko

doi:10.1007/s12282-017-0764-1

Cited by 17 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding independent factors related to CIA, our study revealed only age older than 45 years-old impacted irreversible CIA. This result was similar to previous reports that showed younger ages related to the resumption of menstruation [6][7][8][9][10]. However, Meng et al [10] published their study about this issue in 73 premenopausal breast cancer women who received adjuvant chemotherapy for early-stage breast cancer (Stages I-III) and found that CIA significantly related to age at diagnosis and tamoxifen usage.…”

Section: Discussionsupporting

confidence: 89%

“…This prevalence rate was similar to a previous publication from Japan. Kota et al [7] studied menstruation in 101 premenopausal Stage I-III hormonal receptor-positive Japanese breast cancer women who received chemotherapy. The authors defined CIA as the disappearance of periodic menstruation during chemotherapy and if the menstruation appeared after finishing the course of chemotherapy, this state was defined as a resumption of menstruation.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and Potential Factors Related to Irreversible Chemotherapy-Induced Amenorrhea in Premenopausal Breast Cancer Patients

Suprasert¹,

Khunthong²,

Somwangprasert³

2020

Asian Pac J Cancer Care

View full text Add to dashboard Cite

Objective: To evaluate the prevalence and potential factors related to irreversible chemotherapy-induced amenorrhea (CIA) in premenopausal women with breast cancer. Methods: First diagnosis breast cancer women in Stages I-III who had menstruation within three months before receiving chemotherapy and completed a course of treatment were interviewed about the menstrual cycle after a complete course of chemotherapy and the subsequent menstrual status. Clinical data were retrospectively reviewed. Age at starting chemotherapy was calculated for an optimal cut-off point by using the receiver operating characteristic curve to predict irreversible CIA. The clinicopathological variables were compared using univariate and multivariate analysis to identify the independent factors related to irreversible CIA. Results: One hundred and fifty-four premenopausal breast cancer women who met the inclusion criteria were interviewed. They were treated with chemotherapy between October 1999 and September 2018. The median age at the start of treatment was 43.5 years. One hundred forty-two patients (92.2%) developed CIA and 37 cases subsequently resumed menstruation (RM). Thus, the prevalence of irreversible CIA was 68.2%. The group > 45 years of age, estrogen receptor-positive, progesterone receptor-positive and maintenance treatment with tamoxifen significantly developed irreversible CIA in univariate analysis. However, only the > 45-year-old group was an independent factor for the CIA with an adjusted odds ratio of 23.04. Conclusion: Nearly 70% of premenopausal breast cancer women developed irreversible CIA and the independent factor for this event was being older than 45-years-old when receiving chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Prevalence and Potential Factors Related to Irreversible Chemotherapy-Induced Amenorrhea in Premenopausal Breast Cancer Patients

Suprasert¹,

Khunthong²,

Somwangprasert³

2020

Asian Pac J Cancer Care

View full text Add to dashboard Cite

show abstract

“…Recently, adjuvant chemotherapy has improved the disease-free survival and overall survival of breast cancer patients; however, the detrimental effects caused by chemotherapy remain unclear. 22 – 25 We specifically assessed the changes of serum lipids and apolipoproteins following the administration of chemotherapy in breast cancer patients. When the postoperative patients received chemotherapy, their levels of TC and LDL-C reduced after the first cycle because cancer drugs needed cholesterol depletion to cross the cell membranes.…”

Section: Discussionmentioning

confidence: 99%

<p>Effects of Chemotherapy on Serum Lipids in Chinese Postoperative Breast Cancer Patients</p>

Lü

Zhu

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose Chemotherapy is a comprehensive therapy for breast cancer; nevertheless, its associated adverse effects are drawing increasing attention with the continuous improvement of the efficacy. The changes in serum lipids of breast cancer patients caused by chemotherapy have been reported by previous studies, whereby the former increase the incidence rate of cardiovascular disorders. However, the variations in the changes of serum lipids with different chemotherapy regimens have seldom been reported. Methods From January 2011 to December 2017, 1740 breast cancer patients treated with chemotherapy were recruited at the First Affiliated Hospital of Nanjing Medical University. The chemotherapy regimens included anthracycline-based, taxane-based, and anthracycline-plus-taxane-based regimens, dose-dense and standard-interval regimens. Lipid profiles that contained TG (triglyceride), TC (total cholesterol), HDL-C (high-density lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol) and Lpa (lipoprotein a) levels were collected prior to the first, second and last cycles of chemotherapy. The changes of serum lipids with the same or different chemotherapy regimens were analyzed and compared. Results It was observed that the levels of TG, TC, LDL-C and Lpa increased significantly while that of HDL-C decreased after adjuvant chemotherapy in breast cancer patients (P<0.05). Besides, dose-dense regimens had more influence in TG and HDL-C and less influence in TC and LDL-C than standard-interval regimens. HDL-C was more sensitive to anthracycline-based regimens than taxane-based regimens. The level of TG with anthracycline-plus-taxane-based regimens was higher than that with only anthracycline-based or taxane-based regimens, and the level of HDL-C with anthracycline-plus-taxane-based regimen showed lower than that with taxane-based regimen. Conclusion In summary, this study proposed that dyslipidemia was strongly associated with chemotherapy in Chinese breast cancer patients after operative treatment. Furthermore, the changes in levels of serum lipids varied among patients with different chemotherapy regimens and taxane had less effect on dyslipidemia than anthracycline.

show abstract

“…In this study, amenorrhea was defined as the disappearance of the menstrual cycle during chemotherapy or postchemotherapy for 6 months; if the menstruation appeared periodically again within 1 year postchemotherapy, the state of the women was defined as “recovery of menstruation”. 27 The changes in menstruation postchemotherapy were followed-up.…”

Section: Patients Animals and Methodsmentioning

confidence: 99%

<p>Can Anti-Müllerian Hormone Be a Reliable Biomarker for Assessing Ovarian Function in Women Postchemotherapy?</p>

Li¹,

Liu²,

Ma³

et al. 2020

CMAR

View full text Add to dashboard Cite

Purpose The predictive value of anti-Müllerian hormone (AMH) for ovarian dysfunction postchemotherapy is controversial. This study aimed to evaluate the value of serum AMH levels clinically and theoretically. Patients, Animals, and Methods We detected the serum estradiol, follicular stimulating hormone (FSH), luteinizing hormone (LH), and AMH levels in 144 premenopausal women with breast cancer receiving cyclophosphamide-based chemotherapy. The hormone levels before and postchemotherapy were compared; the correlations among the hormones and amenorrhea and menstrual recovery were analyzed. In addition, the serum AMH levels were detected randomly in 177 normal healthy women and 36 normal female C57BL/6J mice of different ages; meanwhile, the status of ovarian follicles was also examined. Furthermore, 72 Balb/c nude mice with breast cancer were randomly assigned to three groups that received different doses of cyclophosphamide (CTX) (control, 100 mg/kg, and 200 mg/kg), and the alterations in serum AMH levels and ovarian follicles were recorded and analyzed. Results Chemotherapy-induced amenorrhea was associated with prechemotherapy AMH levels, E2 levels, and FSH levels ( P < 0.0001). The recovery of menstruation was associated with prechemotherapy AMH levels ( P < 0.0001), but not with E2 and FSH levels ( P > 0.05). In patients with breast cancer treated with chemotherapy, the serum AMH levels did not differ significantly between the pre- and post-chemotherapy periods in patients aged <35 years ( P > 0.05), whereas a dramatic reduction was detected in patients aged >35 years ( P < 0.0001). In healthy women, the serum AMH levels declined sharply after 35 years of age ( P < 0.0001) and remained relatively stable at a younger age. Similar results were obtained in experiments using normal mice. The cancer-bearing mice exposed to 200 mg/kg CTX exhibited a significant decline in AMH levels and a remarkable decrease in the number of primordial and growing follicles ( P < 0.0001). Conclusion Our results indicate that AMH is an efficient marker for predicting postchemotherapy ovarian function exclusively in premenopausal female patients with breast cancer aged >35 years.

show abstract

Chemotherapy-induced amenorrhea and the resumption of menstruation in premenopausal women with hormone receptor-positive early breast cancer

Abstract: The incidence of CIA, the resumption of menstruation and duration of CIA after chemotherapy depend greatly on the patient's age.

Cited by 17 publications

References 18 publications

Prevalence and Potential Factors Related to Irreversible Chemotherapy-Induced Amenorrhea in Premenopausal Breast Cancer Patients

Prevalence and Potential Factors Related to Irreversible Chemotherapy-Induced Amenorrhea in Premenopausal Breast Cancer Patients

<p>Effects of Chemotherapy on Serum Lipids in Chinese Postoperative Breast Cancer Patients</p>

<p>Can Anti-Müllerian Hormone Be a Reliable Biomarker for Assessing Ovarian Function in Women Postchemotherapy?</p>

Contact Info

Product

Resources

About